Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Real-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors.
William Mullally, Andrew S. Brohl, Aisha Ghaus, Mark Shackleton, Yang Wang, Shahneen Sandhu, Jürgen Becker, Marcin Dzienis, Liam Dwyer, Jenny Lee, Adnan Khattak, Lydia Warburton, Christopher Steer, Wen Xu (2025). Real-world outcomes of immunosuppressed patients with Merkel cell carcinoma treated with immune checkpoint inhibitors.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.9587.
Article308 days agoTwo-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy
Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo (2018). Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy. , 14
Article308 days agoTwo-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy
Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo (2018). Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy. , 14
Article308 days agoHeritable defects in telomere and mitotic function selectively predispose to sarcomas
Mandy L. Ballinger, Swetansu Pattnaik, Piyushkumar A. Mundra, Milita Zaheed, Emma M. Rath, Peter Priestley, Jonathan Baber, Isabelle Ray‐Coquard, Nicholas Isambert, Sylvain Causeret, Winette T.A. van der Graaf, Ajay Puri, Florence Duffaud, Axel Le Cesne, Beatrice Seddon, C.R. Chandrasekar, Joshua D. Schiffman, Andrew S. Brohl, Paul A. James, Jean‐Emmanuel Kurtz, Nicolas Penel, Ola Myklebost, Leonardo A. Meza‐Zepeda, Hilda A. Pickett, Maya Kansara, Nicola Waddell, Olga Kondrashova, John V. Pearson, Andrew P. Barbour, Shuai Li, Tuong L. Nguyen, Diane Fatkin, Robert M. Graham, Eleni Giannoulatou, Melissa J. Green, Warren Kaplan, Shyamsundar Ravishankar, Joseph Copty, Joseph E. Powell, Edwin Cuppen, Kristel van Eijk, Jan H. Veldink, Jin‐Hee Ahn, Jeong Eun Kim, R. Lor Randall, Kathy Tucker, Ian Judson, Rajiv Sarin, Thomas Ludwig, Emmanuelle Génin, Jean‐François Deleuze, Michelle Haber, Glenn M. Marshall, Murray J. Cairns, Jean Yves Blay (2023). Heritable defects in telomere and mitotic function selectively predispose to sarcomas. , 379(6629), DOI: https://doi.org/10.1126/science.abj4784.
Article53 days agoTable S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín‐Broto, Antonio López–Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean Yves Blay, James Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones (2023). Table S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. , DOI: https://doi.org/10.1158/1535-7163.22521156.
Preprint51 days ago